Pegasus Partners Ltd. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,061 shares of the company’s stock after selling 132 shares during the period. Pegasus Partners Ltd.’s holdings in Johnson & Johnson were worth $2,389,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the period. Premier Asset Management LLC increased its position in shares of Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares during the period. Stratford Consulting LLC increased its position in shares of Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after purchasing an additional 16 shares during the period. Iron Financial LLC increased its position in shares of Johnson & Johnson by 0.5% in the second quarter. Iron Financial LLC now owns 3,782 shares of the company’s stock worth $500,000 after purchasing an additional 19 shares during the period. Finally, North Point Portfolio Managers Corp OH increased its position in shares of Johnson & Johnson by 0.7% in the second quarter. North Point Portfolio Managers Corp OH now owns 2,923 shares of the company’s stock worth $387,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 65.91% of the company’s stock.

A number of brokerages recently commented on JNJ. Citigroup raised their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target on the stock in a research report on Monday, October 30th. Leerink Swann restated an “outperform” rating and issued a $165.00 price target (up previously from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Royal Bank Of Canada raised their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Finally, Stifel Nicolaus raised their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $144.59.

Johnson & Johnson (JNJ) traded up $0.65 during trading hours on Friday, reaching $139.98. The company had a trading volume of 5,986,552 shares, compared to its average volume of 5,873,761. The firm has a market capitalization of $376,060.00, a price-to-earnings ratio of 19.61, a PEG ratio of 2.85 and a beta of 0.82. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a fifty-two week low of $109.32 and a fifty-two week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.68 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.40%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

COPYRIGHT VIOLATION NOTICE: “Pegasus Partners Ltd. Sells 132 Shares of Johnson & Johnson (JNJ)” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/12/01/pegasus-partners-ltd-sells-132-shares-of-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.